TriTECM: A tetrafunctional T-cell engaging antibody with built-in risk mitigation of cytokine release syndrome

Overview of attention for article published in Frontiers in immunology, November 2022

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (70th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

twitter: 2 X users

patent: 1 patent

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 23 Mendeley

Summary X Patents Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 805 followers.

Here is one we don’t have on our Periodic Table, yet. A tetrafunctional antibody targeting two tumor antigens, as well as engaging T-cells via CD3e, while also engaging IL6R leading to attenuation of cytokine release. https://t.co/WHDI0P7wwW

21 Dec 2022

Reply Repost Favourite

Newest #research on a novel type of #multispecific #antibodies is out now in @FrontImmunol, describing trispecific #Tcellengagers with built-in risk mitigation of cytokine release. Read more here: https://t.co/eqrUzG8O7A

14 Nov 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.